InvestorsHub Logo
Followers 4
Posts 930
Boards Moderated 0
Alias Born 06/25/2007

Re: None

Sunday, 09/21/2008 11:25:48 PM

Sunday, September 21, 2008 11:25:48 PM

Post# of 5943
IDMI @$3.00. Might receive EMEA (CHMP) opinion this week, or next month, or sometime later this year.

From the IDM I-Hub mb:

Question from the YMB by cybitterman: (Note: PAI is Palo Alto Investors, holds 40% of float of IDM).

Cybear, Meixatech, Tzm, and others. 20-Sep-08 12:46 pm
What is your strategy under the following conditions?

CHMP issues a positive opinion.
Sell or hold?
Wait for EMEA approval?
Trade the swings?
Be patient, wait for company to be sold?

CHMP issues a negative opinion.
Sell immediately?
Hope EMEA disregards CHMP opinion and issues approval?
Sink with the ship?

Your sentiments are appreciated. I am still comtemplating my options. Next week will be VERY interesting. GLTA.

TZM: I have pretty high hopes for MTP's potential as a broad platform for cancer therapy so a positive CHMP opinion might not get the stock price high enough for me to consider selling. Sure I might take some profit on a spike but I have no problem holding my core in this stock all the way till quarterly sales reports on MTP come out.

Just as an example of my pps goals; If we get a positive opinion, I would not be willing to sell a single share below ten dollars as I would expect the company to be bought out for much more than that. I've seen a couple people on this board talk about 6 or 8 dollars upon approval and that is just crazy talk. Upon EMEA approval, this stock would have a takeover price range of 15 to 30 dollars (in my humble opinion) but you might have to be a little patient to get those prices.

A better question would be what do you expect PAI to do upon a positive opinion? I'd tend to think that they might actually hold on to all of their stock so that they can control their own destiny in a takeover scenario. I mean why would they want to sell down their 40 percent stake in IDM just when things start to get interesting? PAI is in this stock because they understand the darkhorse potential that MTP has to be a blockbuster oncology drug and if signs of that potential begin to emerge, look-out because then the takeover price range will be much higher.

Meixatech: I concur.

I am long IDMI. Do your own DD.
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.